

# Resource Summary Report

Generated by [NIF](#) on Aug 1, 2026

## PerCP/Cyanine5.5 anti-human CD19

RRID:AB\_2275547

Type: Antibody

---

### Proper Citation

BioLegend Cat# 302229, RRID:AB\_2275547

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2275547](http://antibodyregistry.org/AB_2275547)

**Proper Citation:** BioLegend Cat# 302229, RRID:AB\_2275547

**Target Antigen:** CD19

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** PerCP/Cyanine5.5 anti-human CD19

**Description:** This monoclonal targets CD19

**Target Organism:** human

**Clone ID:** Clone HIB19

**Antibody ID:** AB\_2275547

**Vendor:** BioLegend

**Catalog Number:** 302229

**Alternative Catalog Numbers:** 302230

**Record Creation Time:** 20250820T030829+0000

**Record Last Update:** 20250820T152723+0000

---

### Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD19.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD19.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 7 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Wientjens C, et al. (2025) Tolerance to ferroptosis facilitates lipid metabolism and pathogenic type 2 immunity in allergic airway inflammation. *Immunity*.

Chandra V, et al. (2024) Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation. *Cancer cell*, 42(1), 85.

Nelde A, et al. (2023) Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. *Blood cancer discovery*, 4(6), 468.

Jalbert E, et al. (2023) Comparative immune responses to *Mycobacterium tuberculosis* in people with latent infection or sterilizing protection. *iScience*, 26(8), 107425.

Seow J, et al. (2022) ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. *Cell reports*, 39(5), 110757.

Graham C, et al. (2021) Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. *Immunity*, 54(6), 1276.

K??rner C, et al. (2017) HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells. *Cell host & microbe*, 22(1), 111.